Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
Go back to Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China| (NASDAQ: VOR) | Delayed: 20.59 +2.20 (11.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.39 | 52 Week High | $ | |||
| Open | $18.72 | 52 Week Low | $ | |||
| Day High | $22.22 | P/E | N/A | |||
| Day Low | $18.67 | EPS | $ | |||
| Volume | 3,911,213 | |||||
